Intranasal PH94B for Management of the Symptoms of Generalized Social Phobia

Phase 2 Completed 90 enrolled Pherin Pharmaceuticals, Inc.

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine the efficacy of PH94B, a new class of therapeutic compound, administered intranasally for the management of acute anxiety in patients diagnosed with generalized social phobia.

Timeline

Start: 2008-02
Primary completion: 2011-02
Completion: 2011-03

Outcome

Met primary endpoint

release “In the Phase 2 trial, which included both a public speaking and a social situation challenge, PH94B significantly improved the primary efficacy endpoint” vistagen.com ↗

release “As in the highly statistically significant (p=0.002) Phase 2 study of PH94B in SAD” vistagen.com ↗

Publications

Liebowitz MR, Salman E, Nicolini H, Rosenthal N, Hanover R, Monti L. Effect of an acute intranasal aerosol dose of PH94B on social and performance anxiety in women with social anxiety disorder. Am J Psychiatry. 2014 Jun;171(6):675-82. doi: 10.1176/appi.ajp.2014.12101342.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Fasedienol	Small molecule	—	Intranasal